Biotechnology Programme


Biotechnology has become one of the key areas of R&D in the last decades, so it was necessary to determine Hungary's needs in this field. To this purpose a national biotechnology study was conducted by the Ministry of Education's Bio- and Agrobiotech-nology Unit in 1998-99 in order to define the research and development priorities within this sector in Hungary. On the basis of this study the “Biotechnology 2000” programme was launched and announced in 1999. In the following years the thematic content and the application rules were refined and updated according to the newly arising needs. The call for proposals were repeated from 2001 to 2003 and will be repeated in this year, too. The aim of the programme is to enhance the knowledge base for research and development in the field of biotechnology, to increase the competitiveness of companies, to develop new methods and services. Applicants are encouraged with subsidies to introduce newly developed, advanced, high-value and competitive biotechnology products. They have to prove that these products and services provide advantages without endangering human health; take into account ethical considerations and give a positive effect on the environment. The defined priorities are:
- Food safety and the application of bio- technology in the food industry;
- Bioinformatics, biogenomics;
- Plant biotechnology, application of biotechnology in plant protection;
- Bioconversion, applying biotechnol ogy in industrial production technologies;
- Bioremediation, application of biotech- nology in environmental issues;
- Using biotechnology in animal breeding and in the veterinary field;
- Biomedicine, biopharmacology, appli- cations in the field of human therapy and diagnostics.
During the last three years Euro17.1 million were gained by the applicants in this programme. Bio- and agro-technology also became priorities in the National Research and Development Programme launched by the Ministry of Education in 2001. In this frame another Euro18.8 million were allocated to this field to strengthen the traditionally strong Hungarian agrofood sector.
Dr. András Siegler, Vice President National Office for Research and Technology,, eMail:



It was a great month for Gedeon Richter Nyrt. (Budapest). At the beginning of February, Hungary’s largest drugmaker announced positive outcomes for two late-stage Phase III trials. In a study sponsored by development partner...



Budapest/Macclesfield – UK-headquartered global ADME-Tox specialist Cyprotex plc has partnered up with Solvo Bio­tech sro to provide the Hungarian firm’s drug transporter assays to its customers in the bio­pharmaceutical...



Budapest/Kraków – In July, illegally planted genetically modified crops made headlines in Hungary, where GMO acreage is banned. Up to 0.1% GMO maize products from Monsanto and Pioneer were discovered at four sites (near...



Budapest – Hungarian vaccine developer Genetic Immunity Kft. (GI) has secured a cash injection of US$25m by signing an agreement with the Budapest-based technology commercialisation company Power of the Dream Ventures, Inc. The...



Budapest/Tokyo – Hungary’s largest drugmaker Gedeon Richter Nyrt. has secured access to the Japanese market for its biosimilar pipeline. In mid-December, Richter CEO Erik Bogsch announced his company had signed a long-term...



Budapest – Richter Group has bagged Swiss gynecology and infertility specialist Preg­Lem Holding SA in a 100 % equity stake worth up to EUR 359m. Hungary’s largest drugmaker expects PregLem’s lead candi­date Esmya as...



Budapest – Hungary’s largest drugmaker Gedeon Richter Ltd. and US partner Forest Laboratory said that a Phase II clinical trial of their orally active drug cariprazine (RGH-188) for bipolar depression produced no “statistically...



Budapest – New results from researchers at the Department of Pathology and Experimental Cancer Research in Budapest suggest that expression of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) on the surface of chronic...



Budapest – ChemAxon, a specialist for chemical informatics software for the life sciences industry, has entered into an agreement with Pfizer. Under the terms of the agreement, Chemaxon will provide its Markush searching and...

Displaying results 1 to 10 out of 89

1-10 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • CYTOS0.66 CHF6.45%
  • EVOLVA1.84 CHF5.14%
  • EPIGENOMICS5.55 EUR4.52%


  • MEDIGENE8.43 EUR-3.77%
  • WILEX3.95 EUR-2.47%
  • BASILEA132.00 CHF-2.08%


  • 4SC4.65 EUR257.7%
  • SYNGENTA430.80 CHF31.8%
  • EVOLVA1.84 CHF21.1%


  • CYTOS0.66 CHF-35.3%
  • MEDIGENE8.43 EUR-30.7%
  • CO.DON2.85 EUR-17.4%


  • WILEX3.95 EUR393.7%
  • 4SC4.65 EUR322.7%
  • FORMYCON28.39 EUR311.4%


  • MOLOGEN5.05 EUR-53.4%
  • BIOFRONTERA2.29 EUR-24.9%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.05.2015

Current issue

All issues